Congenital CMV: what the new AAP guidance means for new parents

The most important infant-health development this week is not a viral birth story. On 21 September 2026 the American Academy of Pediatrics published a clinical report on care of infants with congenital cytomegalovirus (cCMV), with companion papers on newborn screening and eye findings.

### Background
CMV is a common herpesvirus. Most healthy adults who catch it never notice. When a baby is infected before birth, the picture changes. Congenital CMV is a leading infectious cause of hearing loss and a contributor to vision and developmental problems. Many babies look well at delivery. Hearing loss can appear later, which is why “wait and see” has been a poor plan.

TORCH infections (toxoplasmosis, other, rubella, CMV, herpes) sit in the same family of prenatal risks. A JAMA Pediatrics cohort published online the same day is examining how those infections relate to later neurodevelopmental and psychiatric outcomes. That research is association science, not a verdict on any one child. It does explain why pediatric groups keep pushing earlier identification.

### What changed
The AAP report is written for clinicians: how to screen, how to confirm infection, which babies need antiviral discussion, and how to follow hearing, vision, and development. Parallel work from large hospital systems describes what happens when cCMV screening is built into newborn workflows instead of being an afterthought.

Parents will not see a new home test. They should see clearer questions at the hospital and at the first pediatric visits: Was this baby screened? If CMV was found, is hearing already booked? Who owns follow-up?

### Competing viewpoints
Universal newborn CMV screening has supporters who argue hearing-only programs miss babies who pass the first screen and lose hearing later. Critics worry about cost, parental anxiety after a positive result in a well-appearing baby, and uneven access to pediatric infectious-disease and audiology follow-up. Both sides agree that a positive screen without a follow-up path is worse than no screen.

This is not the same debate as childhood vaccine schedules. CMV guidance is about catching an infection already present at birth.

### What to watch next
- Whether more state newborn-screening panels add CMV.
- How hospitals staff audiology and ophthalmology follow-up after a positive result.
- Further data from the TORCH–neurodevelopment cohort as longer outcomes land.

If you are pregnant or have a newborn, ask your clinician whether CMV screening is offered where you deliver and what the follow-up looks like if the result is positive. This article is news context, not medical advice.

Sources: AAP News and Pediatrics online-first reports, 21–22 September 2026; JAMA Pediatrics TORCH cohort, 21 September 2026.